GRAIL Announces CEO Retirement and Successor Appointment

Bob Ragusa to retire as CEO, Josh Ofman, MD, MSHS, named as new CEO

Mar. 13, 2026 at 1:30am

Got story updates? Submit your updates here. ›

GRAIL, a healthcare company focused on early cancer detection, announced that CEO Bob Ragusa will retire effective June 1, 2026. The company's Board of Directors has appointed current President Josh Ofman, MD, MSHS, as the new CEO upon Ragusa's retirement. Ofman has also been appointed to GRAIL's Board of Directors, effective immediately.

Why it matters

GRAIL's mission to detect cancer early is critical to improving patient outcomes, and the leadership transition ensures continuity as the company advances its multi-cancer early detection technology towards regulatory approval and broader access.

The details

Ragusa has led GRAIL during a pivotal period, including the company's spinout from Illumina, commercial growth, and scaling of its North Carolina laboratory operations. Ofman, who has served as GRAIL's President since 2019, brings extensive experience in clinical medicine, biopharmaceutical leadership, health policy, and precision medicine. He has played a central role in shaping GRAIL's strategy, advancing its Galleri evidence program, and strengthening clinical, regulatory, and policy engagement efforts.

  • Bob Ragusa will retire as GRAIL's CEO effective June 1, 2026.
  • Ragusa will remain on GRAIL's Board until June 1, 2026, and plans to serve in a senior advisory role through March of 2027.

The players

Bob Ragusa

The outgoing CEO of GRAIL, who has led the company during a pivotal period and will remain on the Board until June 2026 and in an advisory role through March 2027.

Josh Ofman, MD, MSHS

The incoming CEO of GRAIL, who currently serves as the company's President and has been appointed to the Board of Directors. Ofman brings extensive experience in clinical medicine, biopharmaceutical leadership, health policy, and precision medicine.

Greg Summe

The Chairman of GRAIL's Board of Directors.

GRAIL, Inc.

A healthcare company whose mission is to detect cancer early when it can be cured.

Got photos? Submit your photos here. ›

What they’re saying

“Bob's leadership during a pivotal period — including the spinout from Illumina, commercial growth, and the scaling of our North Carolina laboratory operations — has been instrumental in strengthening GRAIL's foundation for long-term growth.”

— Greg Summe, Chairman of GRAIL's Board of Directors

“Leading GRAIL and working alongside an extraordinary team united in the mission to transform cancer screening and save lives has been the greatest honor of my four decades in healthcare.”

— Bob Ragusa

“What inspires me most about GRAIL is our bold ambition to solve one of society's greatest public health challenges. We are leading the multi-cancer early detection field with the most comprehensive body of evidence and meaningful progress toward regulatory approval and reimbursement.”

— Josh Ofman, MD, MSHS

What’s next

Ofman will assume the role of GRAIL's CEO on June 1, 2026, upon Ragusa's retirement. Ragusa will remain on GRAIL's Board until June 1, 2026, and plans to serve in a senior advisory role through March of 2027.

The takeaway

GRAIL's leadership transition ensures continuity as the company advances its mission to detect cancer early and improve patient outcomes. Ofman's experience and proven ability to translate vision into results position him to lead GRAIL's next chapter of growth and impact.